Quantbot Technologies LP Buys Shares of 1,267 Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Quantbot Technologies LP purchased a new stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,267 shares of the company’s stock, valued at approximately $51,000.

A number of other hedge funds have also modified their holdings of IONS. Mather Group LLC. grew its holdings in Ionis Pharmaceuticals by 35.8% during the 2nd quarter. Mather Group LLC. now owns 911 shares of the company’s stock valued at $39,000 after buying an additional 240 shares during the last quarter. Vanguard Personalized Indexing Management LLC lifted its position in shares of Ionis Pharmaceuticals by 3.5% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 7,624 shares of the company’s stock valued at $363,000 after acquiring an additional 261 shares in the last quarter. Nicollet Investment Management Inc. boosted its stake in shares of Ionis Pharmaceuticals by 1.5% during the third quarter. Nicollet Investment Management Inc. now owns 20,402 shares of the company’s stock valued at $817,000 after acquiring an additional 294 shares during the last quarter. Amalgamated Bank increased its position in Ionis Pharmaceuticals by 3.1% during the 3rd quarter. Amalgamated Bank now owns 9,957 shares of the company’s stock worth $399,000 after purchasing an additional 300 shares in the last quarter. Finally, GAMMA Investing LLC raised its stake in Ionis Pharmaceuticals by 83.9% in the 3rd quarter. GAMMA Investing LLC now owns 664 shares of the company’s stock valued at $27,000 after purchasing an additional 303 shares during the last quarter. 93.86% of the stock is owned by hedge funds and other institutional investors.

Ionis Pharmaceuticals Stock Up 3.7 %

Shares of NASDAQ:IONS opened at $38.11 on Friday. The company has a market capitalization of $6.02 billion, a price-to-earnings ratio of -15.62 and a beta of 0.35. The company has a 50 day moving average of $37.63 and a two-hundred day moving average of $42.31. Ionis Pharmaceuticals, Inc. has a 52-week low of $33.33 and a 52-week high of $54.44. The company has a quick ratio of 8.82, a current ratio of 8.91 and a debt-to-equity ratio of 1.86.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. Guggenheim lowered their price target on shares of Ionis Pharmaceuticals from $70.00 to $65.00 and set a “buy” rating for the company in a report on Wednesday, October 9th. Needham & Company LLC reissued a “buy” rating and set a $60.00 price target on shares of Ionis Pharmaceuticals in a research note on Thursday, November 7th. JPMorgan Chase & Co. lifted their price objective on Ionis Pharmaceuticals from $50.00 to $55.00 and gave the company a “neutral” rating in a research report on Monday, August 26th. Royal Bank of Canada reiterated an “outperform” rating and set a $70.00 target price on shares of Ionis Pharmaceuticals in a research report on Thursday, September 26th. Finally, Wells Fargo & Company decreased their price target on Ionis Pharmaceuticals from $82.00 to $77.00 and set an “overweight” rating on the stock in a research note on Thursday, November 7th. Two analysts have rated the stock with a sell rating, five have issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $60.65.

Insider Buying and Selling at Ionis Pharmaceuticals

In related news, CEO Brett P. Monia sold 6,630 shares of the business’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $38.05, for a total value of $252,271.50. Following the completion of the sale, the chief executive officer now directly owns 167,393 shares of the company’s stock, valued at $6,369,303.65. The trade was a 3.81 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Eric Swayze sold 1,194 shares of the stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $37.92, for a total value of $45,276.48. Following the transaction, the executive vice president now directly owns 33,713 shares in the company, valued at approximately $1,278,396.96. This represents a 3.42 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 7,877 shares of company stock worth $299,578 in the last 90 days. 2.71% of the stock is owned by corporate insiders.

Ionis Pharmaceuticals Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.